The Cole Eye Institute Retina Summit took place on Friday, May 5, 2017

This Summit provides a comprehensive medical and surgical update in new advancements in retinal imaging critical to enhance the accuracy of diagnosis and to improve treatment outcomes for diseases of the retina and vitreoretinal interface.

Session Topics

Long-Term Treatment Outcomes in Exudative AMD – Sophie J. Bakri, MD
Beyond Anti VEGF: Ang-2 and PDGF for AMD Treatment – Peter Kaiser, MD
Complement Inhibition for Non-Exudative AMD –  Rishi P. Singh, MD
Prognostic Biomarkers for AMD – Justis P. Ehlers, MD
Comparison of Treatment Algorithms in AMD – Dante J. Pieramici, MD
PANEL: AMD – David Brown, MD 

AMD

  • AMD

    Drs. Bakri, Kaiser, Singh, Ehlers, and Pieramici
  • *Slides available upon request for this session.

Release Date: August 1, 2017

Expiration Date: August 1, 2018

Target Audience
This activity is intended to meet the needs of retina specialists, comprehensive ophthalmologists, retina fellows and healthcare providers who are interested in applying the most recent advancements in the retinal medicine field, including emerging techniques for imaging and treating retinal and vitreoretinal diseases.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • To provide an overview of potential biomarkers in age-related macular degeneration.
    To provide an overview of the clinical context of biomarker utility
  • Identify therapeutic options for the management of treatment-resistant AMD
  • Summarize recent clinical trial data and what we’ve learned for retinal diseases

 

Criteria for Success
In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at jgoldman@akhcme.com.

CME Credit provided by AKH Inc., Advancing Knowledge in Healthcare

 

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

 

FACULTY DISCLOSURES

Sophie J. Bakri, MD

  • Nothing to disclose

Justis Ehlers, MD

      • Consultant
        Alcon, Thrombogenics, Santen, Zeiss, Alimera, Leica, Genentech
      • Contracted Research
        Alcon, Genentech, Regeneron

Peter K. Kaiser, MD

    • Consultant
      Alcon, Allergan, Allegro, Aerpio, Bausch and Lomb, Bayer, Benitec, Biogen Idec, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside, Eyevensys, Ocunexus, Omeros, ONL, Regeneron, Novartis, Kanghong, Ophthotech, Ohr, Santen, SciFluor, Shire, Thrombogenics

FACULTY DISCLOSURES

Dante J Pieramici

      • Consultant
        Genentech, Regeneron
    •  Contracted Research
      Genentech, Regeneron, Allergan, Janssen, ophthotec

Rishi P. Singh

    • Consultant
      Genentech, Regeneron, Allergan
    • Contracted Research
      Genentech, Regeneron, Allergan, Apellis

PLANNER DISCLOSURES

Dorothy Caputo, MA, BSN, RN – CE Director of Accreditations

-Nothing to disclose

MCME Global Staff and Planners

-Nothing to disclose

AKH Planners and Reviewers

-Nothing to disclose

 

Commercial Support

This activity is supported by an educational grant from Alcon, Genentech and Regeneron.

 

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

 

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

 

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo

X

PRE-QUESTIONS

Please answer the following pre-question before moving on to the session presentation.

First Name*
Last Name*
Email*

After 5 years of anti-VEGF therapy:

*
Most patients have some residual fluid on OCT
CNV lesion size on FA tends to grow
Half of patients maintain 20/40 or better
None of the above
All of the above

All of the following pathways have been linked to AMD prevalence and progression except for:

*
Lectin pathway
Alternative complement pathway
Classic pathway
VEGF pathway